Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01318551
Recruitment Status : Completed
First Posted : March 18, 2011
Last Update Posted : October 13, 2014
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single dose group stratified study in renal impaired and healthy subjects.

Condition or disease Intervention/treatment Phase
Anemia Drug: BAY85-3934 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Investigation of Pharmacokinetics, Safety, Tolerability, and Pharmacodynamic Effects of BAY85-3934 in Male and Female Subjects With Renal Impairment and in Age- and Weight-matched Healthy Subjects Following a Single Oral Dose of 20 mg and 40 mg (Optional) BAY 85-3934 Administered as Tablets in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
Study Start Date : March 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia

Arm Intervention/treatment
Experimental: Arm 1 Drug: BAY85-3934
single dose, 20 mg

Experimental: Arm 2 Drug: BAY85-3934
single dose, 40 mg (optional)

Experimental: Arm 3 Drug: BAY85-3934
single dose, 80 mg (optional)




Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: Up to 4 weeks ]

Secondary Outcome Measures :
  1. Area under the plasma concentration versus time curve (AUC) of BAY85-3934 [ Time Frame: Day 0 to day 4 ]
  2. Peak Plasma Concentration (Cmax) of BAY85-3934 [ Time Frame: Day 0 to day 4 ]
  3. Dose-normalized area under the plasma concentration-time curve (AUCnorm) of BAY85-3934 [ Time Frame: Day 0 to day 4 ]
  4. Dose- and body weight-normalised Cmax (Cmax-norm) of BAY85-3934 [ Time Frame: Day 0 to day 4 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The informed consent must be signed before any study-specific tests or procedures are done.
  • Female subjects with no child-bearing potential (postmenopausal women with 12 months of spontaneous amenorrhea or with 6 months of spontaneous amenorrhea and serum FSH concentrations >30 mIU/mL, women with 6 weeks post bilateral ovariectomy, woman with bilateral tubal ligation, and women with hysterectomy).
  • Male subjects who agree to use 2 forms of effective contraception during the study and for 12 weeks after receiving the study drug. This must include a condom with spermicide gel for 21 days after drug administration.
  • Male subjects who agree not to act as sperm donors for 12 weeks after dosing.
  • Age: ≥18 and ≤79 years at the pre-study visit.
  • Body mass index (BMI): ≥18 and ≤34 kg/m2.
  • Ethnicity: white.
  • • Subjects participating in this trial and having received 20 mg BAY 85 3934 are encouraged to participate in the following optionally 40 mg and 80 mg study parts.
  • Ability to understand and follow study-related instructions.
  • For subjects with renal impairment:

    • In diseased subjects: CLCR <90 mL/min determined from a serum creatinine control.
    • In diseased subjects: stable renal disease, ie a serum creatinine value determined at least 3 months before the pre-study visit during routine diagnostics independently of the study should not vary by more than 20% from the serum creatinine value determined at the pre-study visit.
  • For healthy subjects:

    • Mean age and body weight in Group 1 or Group 6 or Group 11 (control group, healthy subjects) and Groups 2 to 5 and Groups 7 to 10 and Groups 12 to 15 should not vary by more than +10 years and +10 kg, respectively..
    • In diseased subjects: CLCR ≥90 mL/min determined from a serum creatinine control.

Exclusion Criteria:

  • Participation in another clinical trial during the preceding 3 months for multiple-dose studies and 1 month for single-dose studies; (final examination from previous study to first treatment of new study).
  • Exclusion periods from other studies or simultaneous participation in other clinical studies.
  • Donation of >100 mL of blood within 4 weeks before the first study drug administration or >500 mL in the preceding 3 months.
  • Medical disorder that would impair the subject's ability to complete the study in the opinion of the investigator.
  • Severe infection or any clinically significant illness within 4 weeks prior to dosing.
  • Known hypersensitivity to the study drugs (active substances, or excipients of the preparations).
  • Known severe allergies, non-allergic drug reactions, or multiple drug allergies.
  • Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (HCV Ab), human immune deficiency virus antibodies (HIV 1/2 Ab).
  • Regular use of recreational drugs, eg carnitine products, anabolics.
  • Regular daily consumption of ≥ 0.5 L of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form.
  • Suspicion of drug or alcohol abuse.
  • Positive urine drug screening.
  • Regular daily consumption of >25 cigarettes.
  • Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety.
  • Use of medication within the 2 weeks preceding the study which could interfere with the investigational product.
  • For subjects with renal impairment:

    • Acute renal failure.
    • Acute nephritis.
    • Nephrotic syndrome.
    • Any organ transplant < 1 year before participation in this study.
    • Failure of any other major organ system other than the kidney.
    • Relevant impairment in liver function of by option of the investigator.
    • Pre-existing diseases for which it can be assumed that the absorption of the study drugs will not be normal (ie relevant malabsorption, chronic diarrhea).
    • Diastolic blood pressure (DBP) >100 mmHg and/or systolic blood pressure (SBP) >180 mmHg (at the pre-study examination; readings taken at the end of the dosing interval of antihypertensive medication, if any).
    • Heart rate <45 or >100 BPM for subject aged 18 to ≤50 years and <55 or >110 BPM for subject aged >50 to ≤79 years at screening visit.
    • Significant uncorrected rhythm or conduction disturbances such as a second- or third-degree AV block without a cardiac pacemaker or episodes of sustained ventricular tachycardia, or by option of the investigator.
    • Diagnosed malignancy within the past 5 years.
    • Psychiatric disorders which may disable the subjects to consent.
    • Change in chronic medications <4 weeks prior to dosing.
    • Concomitant use of any medication except medications necessary for the treatment of the kidney disease or related complications.
  • For healthy subjects

    • Subjects with conspicuous findings in medical history or pre-study examination by option of the investigator.
    • A history of relevant diseases of vital organs, of the central nervous system or other organs.
    • Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal.
    • Systolic blood pressure <100 mmHg or >145 mmHg.
    • Diastolic blood pressure >95 mmHg.
    • Heart rate <45 or >95 BPM for subject aged 18 to ≤50 years and <55 or >95 BPM for subject aged >50 to ≤79 years at screening visit.
    • Clinically relevant findings in the ECG such as a second- or third-degree AV block, clinically relevant prolongation of the QRS complex >120 ms or of the QTc interval >450 ms for men and >470 ms for women of by option of the investigator.
    • Clinically relevant deviations of the screened laboratory parameters in clinical chemistry, hematology, or urinalysis from reference range of by option of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01318551


Locations
Layout table for location information
Germany
Kiel, Schleswig-Holstein, Germany, 24105
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01318551    
Other Study ID Numbers: 15557
2011-000055-16 ( EudraCT Number )
First Posted: March 18, 2011    Key Record Dates
Last Update Posted: October 13, 2014
Last Verified: October 2014
Keywords provided by Bayer:
Anemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Hematologic Diseases